Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
5 participants
INTERVENTIONAL
2017-02-13
2019-04-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Antiretroviral therapy
Stopping antiretroviral therapy
no drug
Stopping antiretroviral therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
no drug
Stopping antiretroviral therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Nadir CD4\>200/mm3
* CD4/CD8 ratio\> 0.5
* Continuous antiretroviral therapy for more than 2 years
* Plasma Human Immunodeficiency Virus (HIV) 1 Ribonucleic acid (RNA) \<50 copies/ml in the last 2 years
* Viral Load (VL)\<20copies at inclusion
* Patients who are willing to participate and who understand the trial (particularly, the obligation to have protected intercourse during the study).
* Informed consent
* Short half-life treatment
* Health insurance
* A subset of CD4 (T4cells) express CD32a.
Exclusion Criteria
* Pregnancy
* Human immunodeficiency virus (HIV)-2 co infection
* Thrombopenia
* Neurological events during primary infection
* Hepatitis B + (HBV+)
* Hepatitis C + (HCV+)
* Cancer during the last 5 years.
* Life expectancy \< 12 months
* Autoimmunity
* Acute infectious disease in the last 60 days.
* Hemoglobin\<7g/dl
* Glomerular filtration \< 60ml/min
* Refusing protected intercourse
* Risk of HIV transmission
* Psychiatric disorders.
* Alcool and drug abuse
* Involvement in another clinical trial evaluating a therapeutic.
* Being under tutorship
* Being deprived of liberty
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laboratoire de Virologie Moléculaire de Montpellier
UNKNOWN
Centre Hospitalier Régional d'Orléans
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
LAURENT HOCQUELOUX
Role: STUDY_DIRECTOR
CHR ORLEANS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chr Orleans
Orléans, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Descours B, Petitjean G, Lopez-Zaragoza JL, Bruel T, Raffel R, Psomas C, Reynes J, Lacabaratz C, Levy Y, Schwartz O, Lelievre JD, Benkirane M. CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses. Nature. 2017 Mar 23;543(7646):564-567. doi: 10.1038/nature21710. Epub 2017 Mar 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHRO 2016-05
Identifier Type: -
Identifier Source: org_study_id